Trialbee, a global technology provider for patient matching and engagement in clinical trials, announced a partnership with Datavant aiming to more effectively and efficiently recruit clinical trial participants.
“We are solving for the Investigator fatigue and demotivation caused by unguided mega screening for patient recruitment and the low results it produces,” said Lollo Eriksson, chief executive officer of Trialbee. “This partnership with Datavant will significantly expand our access to real world data (RWD) and ability to choose the information assets that are most relevant for any given trial. This unique collaboration will improve specificity and drive the right patients to clinical trials, improving efficiency and time to last patient enrolled.”
Trialbee is the global patient recruitment and engagement company with integrated patient sourcing using RWD from claims data, electronic health records data and digital outreach to the general public. Trialbee will use Datavant’s open data ecosystem to power its innovative clinical trial recruitment and patient engagement solutions, analyzing de-identified data to determine the characteristics of patients who may be eligible and motivated to participate in a clinical trial.
“Trialbee is tackling a critical problem with a fresh perspective: how to more effectively recruit patients to clinical trials and keep them engaged once they are enrolled,” said Travis May, chief executive officer of Datavant. “We are thrilled for the partnership to support their access to real-world data sources across Datavant’s open data ecosystem.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.